Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 7, 2025

Despite the advancements in targeted biologic therapy for immune-mediated inflammatory diseases (IMIDs), significant challenges persist, including drug maintenance, primary and secondary non-responses, adverse effects. Recent data have strengthened evidence supporting stem cell as an experimental salvage into a standard treatment option. preclinical clinical studies suggested that chimeric antigen receptor T (CAR-T) therapy, which depleting tissue bone marrow B cells, may lead to improvement, even inducing long-lasting remissions patients with IMIDs. In this review, we address unmet needs of delineate critical differences between transplantation CAR-T evaluate current status IMIDs explore its potential existing limitations.

Язык: Английский